 Lilliam Ambroggio
Concepts (294)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Community-Acquired Infections | 43 | 2025 | 176 | 12.840 |
Why?
| | Pneumonia | 43 | 2025 | 656 | 10.820 |
Why?
| | Anti-Bacterial Agents | 26 | 2025 | 1866 | 3.690 |
Why?
| | Emergency Service, Hospital | 26 | 2026 | 2193 | 3.030 |
Why?
| | Pneumonia, Bacterial | 10 | 2025 | 117 | 2.790 |
Why?
| | Respiratory Tract Infections | 13 | 2025 | 385 | 2.260 |
Why?
| | Child | 97 | 2026 | 22414 | 2.050 |
Why?
| | Infant | 54 | 2025 | 9843 | 1.600 |
Why?
| | Severity of Illness Index | 13 | 2025 | 2903 | 1.580 |
Why?
| | Guideline Adherence | 5 | 2023 | 566 | 1.520 |
Why?
| | Child, Preschool | 54 | 2025 | 11512 | 1.520 |
Why?
| | Macrolides | 4 | 2021 | 68 | 1.450 |
Why?
| | Pneumonia, Mycoplasma | 5 | 2025 | 55 | 1.430 |
Why?
| | Ultrasonography | 3 | 2024 | 761 | 1.420 |
Why?
| | Wounds, Gunshot | 3 | 2026 | 248 | 1.420 |
Why?
| | Length of Stay | 11 | 2025 | 1263 | 1.400 |
Why?
| | Hospitals, Pediatric | 13 | 2025 | 532 | 1.330 |
Why?
| | Quality Improvement | 8 | 2025 | 1254 | 1.310 |
Why?
| | beta-Lactams | 3 | 2015 | 34 | 1.290 |
Why?
| | Pneumonia, Pneumococcal | 2 | 2025 | 47 | 1.260 |
Why?
| | Hospitalization | 21 | 2025 | 2264 | 1.220 |
Why?
| | Streptococcus pneumoniae | 3 | 2025 | 169 | 1.180 |
Why?
| | Firearms | 3 | 2026 | 400 | 1.170 |
Why?
| | Propensity Score | 5 | 2025 | 332 | 1.090 |
Why?
| | Biomedical Research | 4 | 2023 | 708 | 1.060 |
Why?
| | Practice Guidelines as Topic | 5 | 2019 | 1570 | 1.020 |
Why?
| | Asthma | 6 | 2023 | 1920 | 1.020 |
Why?
| | Prospective Studies | 33 | 2025 | 7777 | 1.010 |
Why?
| | Bacteremia | 4 | 2019 | 216 | 1.010 |
Why?
| | Humans | 112 | 2026 | 141754 | 0.980 |
Why?
| | Adolescent | 45 | 2026 | 22130 | 0.920 |
Why?
| | Antigens, Bacterial | 1 | 2025 | 125 | 0.880 |
Why?
| | Retrospective Studies | 31 | 2025 | 16374 | 0.850 |
Why?
| | Credentialing | 1 | 2024 | 21 | 0.850 |
Why?
| | Outpatients | 4 | 2024 | 421 | 0.820 |
Why?
| | Mycoplasma pneumoniae | 7 | 2025 | 54 | 0.790 |
Why?
| | Male | 58 | 2026 | 70179 | 0.760 |
Why?
| | Thiamine Deficiency | 1 | 2022 | 10 | 0.750 |
Why?
| | Radiography, Thoracic | 4 | 2022 | 179 | 0.750 |
Why?
| | Point-of-Care Systems | 1 | 2024 | 188 | 0.720 |
Why?
| | Patient Readmission | 5 | 2024 | 708 | 0.710 |
Why?
| | Communicable Diseases | 1 | 2023 | 161 | 0.700 |
Why?
| | Female | 59 | 2026 | 75943 | 0.700 |
Why?
| | Suicide | 2 | 2025 | 671 | 0.680 |
Why?
| | Evidence-Based Medicine | 2 | 2015 | 750 | 0.680 |
Why?
| | Ambulatory Care | 5 | 2025 | 587 | 0.650 |
Why?
| | Mental Health Services | 1 | 2025 | 447 | 0.650 |
Why?
| | Patient Discharge | 3 | 2022 | 933 | 0.580 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2022 | 238 | 0.580 |
Why?
| | Adrenal Cortex Hormones | 4 | 2023 | 501 | 0.560 |
Why?
| | Sepsis | 3 | 2022 | 621 | 0.550 |
Why?
| | Pneumonia, Necrotizing | 1 | 2017 | 1 | 0.550 |
Why?
| | Drug Prescriptions | 3 | 2020 | 267 | 0.540 |
Why?
| | Respiratory Syncytial Virus, Human | 3 | 2023 | 77 | 0.540 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2017 | 23 | 0.520 |
Why?
| | Mass Screening | 3 | 2024 | 1313 | 0.520 |
Why?
| | Pediatrics | 4 | 2024 | 1100 | 0.500 |
Why?
| | Viruses | 3 | 2023 | 163 | 0.490 |
Why?
| | Research Design | 4 | 2021 | 1146 | 0.480 |
Why?
| | Alcoholism | 1 | 2022 | 823 | 0.460 |
Why?
| | Microbiota | 4 | 2024 | 768 | 0.440 |
Why?
| | Administration, Oral | 4 | 2024 | 803 | 0.430 |
Why?
| | Biomarkers | 10 | 2025 | 4190 | 0.430 |
Why?
| | Child, Hospitalized | 4 | 2024 | 53 | 0.430 |
Why?
| | Multiplex Polymerase Chain Reaction | 3 | 2025 | 53 | 0.420 |
Why?
| | Administration, Intravenous | 2 | 2024 | 161 | 0.410 |
Why?
| | Clinical Decision-Making | 4 | 2022 | 339 | 0.410 |
Why?
| | Treatment Failure | 3 | 2024 | 354 | 0.410 |
Why?
| | ROC Curve | 4 | 2025 | 590 | 0.410 |
Why?
| | Research | 2 | 2016 | 455 | 0.400 |
Why?
| | Pneumonia, Ventilator-Associated | 2 | 2025 | 55 | 0.380 |
Why?
| | Adrenomedullin | 2 | 2021 | 5 | 0.360 |
Why?
| | Virus Diseases | 2 | 2024 | 215 | 0.360 |
Why?
| | Metabolomics | 3 | 2025 | 704 | 0.340 |
Why?
| | Fever | 3 | 2022 | 308 | 0.320 |
Why?
| | Odds Ratio | 3 | 2022 | 1057 | 0.320 |
Why?
| | Respiratory Sounds | 3 | 2022 | 109 | 0.320 |
Why?
| | Prognosis | 7 | 2023 | 4080 | 0.310 |
Why?
| | Hospital Charges | 1 | 2009 | 45 | 0.310 |
Why?
| | Simplexvirus | 1 | 2009 | 82 | 0.310 |
Why?
| | United States | 12 | 2024 | 15310 | 0.300 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2025 | 614 | 0.300 |
Why?
| | Herpes Simplex | 1 | 2009 | 95 | 0.290 |
Why?
| | Critical Illness | 6 | 2025 | 837 | 0.290 |
Why?
| | Health Resources | 1 | 2009 | 129 | 0.280 |
Why?
| | Pandemics | 4 | 2024 | 1656 | 0.280 |
Why?
| | Cohort Studies | 12 | 2025 | 5815 | 0.280 |
Why?
| | Treatment Outcome | 8 | 2024 | 11181 | 0.280 |
Why?
| | Suicidal Ideation | 2 | 2025 | 545 | 0.280 |
Why?
| | Feces | 2 | 2021 | 505 | 0.260 |
Why?
| | Utilization Review | 2 | 2018 | 41 | 0.260 |
Why?
| | Drug Therapy, Combination | 3 | 2015 | 1041 | 0.260 |
Why?
| | Case-Control Studies | 6 | 2025 | 3597 | 0.260 |
Why?
| | Practice Patterns, Physicians' | 4 | 2025 | 1344 | 0.250 |
Why?
| | Caregivers | 2 | 2026 | 943 | 0.240 |
Why?
| | Penicillins | 2 | 2023 | 59 | 0.240 |
Why?
| | Ohio | 2 | 2016 | 140 | 0.230 |
Why?
| | Serogroup | 1 | 2025 | 45 | 0.230 |
Why?
| | Data Interpretation, Statistical | 2 | 2018 | 377 | 0.230 |
Why?
| | Amoxicillin | 1 | 2025 | 35 | 0.230 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2024 | 1634 | 0.230 |
Why?
| | Inpatients | 2 | 2021 | 512 | 0.230 |
Why?
| | Risk Factors | 9 | 2025 | 10482 | 0.230 |
Why?
| | Influenza, Human | 2 | 2023 | 626 | 0.220 |
Why?
| | Bacteriological Techniques | 1 | 2025 | 67 | 0.220 |
Why?
| | Bacteria | 4 | 2025 | 881 | 0.220 |
Why?
| | Nasal Mucosa | 1 | 2025 | 111 | 0.220 |
Why?
| | Interrupted Time Series Analysis | 1 | 2024 | 80 | 0.210 |
Why?
| | Asymptomatic Infections | 1 | 2024 | 36 | 0.210 |
Why?
| | Infant, Newborn | 7 | 2025 | 6289 | 0.210 |
Why?
| | Protein Precursors | 2 | 2021 | 134 | 0.210 |
Why?
| | Critical Pathways | 1 | 2025 | 106 | 0.210 |
Why?
| | Intensive Care Units, Pediatric | 3 | 2025 | 270 | 0.210 |
Why?
| | Diagnostic Errors | 1 | 2025 | 178 | 0.210 |
Why?
| | Logistic Models | 4 | 2021 | 2092 | 0.200 |
Why?
| | Nervous System Diseases | 2 | 2016 | 277 | 0.200 |
Why?
| | Family Characteristics | 1 | 2024 | 192 | 0.190 |
Why?
| | Pennsylvania | 2 | 2015 | 134 | 0.190 |
Why?
| | Coinfection | 1 | 2024 | 137 | 0.190 |
Why?
| | Pneumonia, Aspiration | 2 | 2019 | 17 | 0.190 |
Why?
| | Thiamine | 1 | 2022 | 19 | 0.190 |
Why?
| | Health Education | 1 | 2026 | 364 | 0.190 |
Why?
| | Delphi Technique | 1 | 2024 | 313 | 0.190 |
Why?
| | Follow-Up Studies | 4 | 2022 | 5212 | 0.180 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2023 | 131 | 0.180 |
Why?
| | Heart Defects, Congenital | 1 | 2009 | 884 | 0.180 |
Why?
| | Consensus | 1 | 2024 | 547 | 0.180 |
Why?
| | Pleural Effusion | 1 | 2022 | 61 | 0.180 |
Why?
| | Nucleic Acids | 1 | 2022 | 71 | 0.170 |
Why?
| | Arthritis, Infectious | 1 | 2022 | 73 | 0.170 |
Why?
| | Blood Culture | 2 | 2019 | 24 | 0.170 |
Why?
| | Safety | 1 | 2023 | 356 | 0.170 |
Why?
| | Pediatric Emergency Medicine | 1 | 2021 | 24 | 0.170 |
Why?
| | Aftercare | 1 | 2022 | 218 | 0.170 |
Why?
| | Quality of Life | 2 | 2023 | 3014 | 0.170 |
Why?
| | Gastroenteritis | 1 | 2021 | 68 | 0.160 |
Why?
| | Tobacco Smoke Pollution | 1 | 2023 | 256 | 0.160 |
Why?
| | Pseudomonas Infections | 1 | 2022 | 230 | 0.160 |
Why?
| | International Cooperation | 1 | 2021 | 203 | 0.160 |
Why?
| | Proteome | 1 | 2024 | 485 | 0.160 |
Why?
| | Cytomegalovirus Vaccines | 1 | 2019 | 5 | 0.160 |
Why?
| | Osteomyelitis | 1 | 2022 | 143 | 0.160 |
Why?
| | State Medicine | 1 | 2019 | 25 | 0.160 |
Why?
| | Intensive Care Units | 3 | 2021 | 871 | 0.160 |
Why?
| | Societies | 1 | 2019 | 39 | 0.160 |
Why?
| | Clinical Deterioration | 1 | 2019 | 9 | 0.150 |
Why?
| | Iatrogenic Disease | 1 | 2020 | 71 | 0.150 |
Why?
| | Public Health | 1 | 2024 | 587 | 0.150 |
Why?
| | Physicians | 2 | 2021 | 942 | 0.150 |
Why?
| | Non-Randomized Controlled Trials as Topic | 1 | 2018 | 20 | 0.150 |
Why?
| | Central Nervous System Diseases | 1 | 2019 | 73 | 0.150 |
Why?
| | Diarrhea | 1 | 2020 | 184 | 0.150 |
Why?
| | Prednisolone | 2 | 2020 | 69 | 0.150 |
Why?
| | Cytomegalovirus | 1 | 2019 | 163 | 0.150 |
Why?
| | Infectious Disease Medicine | 1 | 2018 | 12 | 0.140 |
Why?
| | Influenza B virus | 1 | 2018 | 44 | 0.140 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2018 | 46 | 0.140 |
Why?
| | Cytomegalovirus Infections | 1 | 2019 | 197 | 0.140 |
Why?
| | Observer Variation | 2 | 2016 | 357 | 0.140 |
Why?
| | Prednisone | 2 | 2020 | 230 | 0.140 |
Why?
| | Proteomics | 1 | 2024 | 1138 | 0.140 |
Why?
| | Factor Analysis, Statistical | 1 | 2018 | 296 | 0.140 |
Why?
| | Gastrointestinal Diseases | 1 | 2020 | 207 | 0.140 |
Why?
| | Anti-Asthmatic Agents | 1 | 2020 | 273 | 0.140 |
Why?
| | Pilot Projects | 1 | 2023 | 1826 | 0.130 |
Why?
| | Cytokines | 1 | 2025 | 2100 | 0.130 |
Why?
| | Antibody Formation | 1 | 2018 | 298 | 0.130 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2018 | 151 | 0.130 |
Why?
| | Patient Transfer | 1 | 2019 | 181 | 0.130 |
Why?
| | Immunization Schedule | 1 | 2018 | 203 | 0.130 |
Why?
| | Fatal Outcome | 1 | 2017 | 309 | 0.130 |
Why?
| | Mental Disorders | 1 | 2025 | 1130 | 0.120 |
Why?
| | Models, Statistical | 1 | 2020 | 671 | 0.120 |
Why?
| | Dexamethasone | 2 | 2020 | 380 | 0.120 |
Why?
| | Intersectoral Collaboration | 1 | 2016 | 60 | 0.120 |
Why?
| | Killer Cells, Natural | 1 | 2019 | 471 | 0.120 |
Why?
| | Physical Examination | 1 | 2017 | 242 | 0.120 |
Why?
| | Health Services Research | 1 | 2018 | 406 | 0.120 |
Why?
| | Anaphylaxis | 1 | 2017 | 107 | 0.120 |
Why?
| | Efficiency, Organizational | 1 | 2016 | 139 | 0.120 |
Why?
| | Cross-Sectional Studies | 5 | 2022 | 5697 | 0.120 |
Why?
| | Emergency Medicine | 1 | 2018 | 246 | 0.120 |
Why?
| | Hospitalists | 1 | 2019 | 251 | 0.110 |
Why?
| | Venous Thromboembolism | 1 | 2020 | 337 | 0.110 |
Why?
| | Microbial Sensitivity Tests | 2 | 2017 | 370 | 0.110 |
Why?
| | Azithromycin | 2 | 2025 | 98 | 0.110 |
Why?
| | Palliative Care | 1 | 2021 | 822 | 0.110 |
Why?
| | Inservice Training | 1 | 2015 | 122 | 0.110 |
Why?
| | Hypoxia | 2 | 2024 | 1165 | 0.110 |
Why?
| | Multivariate Analysis | 2 | 2016 | 1498 | 0.100 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 5974 | 0.100 |
Why?
| | Societies, Medical | 1 | 2018 | 859 | 0.100 |
Why?
| | Reproducibility of Results | 3 | 2017 | 3356 | 0.100 |
Why?
| | Precision Medicine | 1 | 2017 | 434 | 0.100 |
Why?
| | Influenza Vaccines | 1 | 2018 | 551 | 0.100 |
Why?
| | Binomial Distribution | 1 | 2012 | 8 | 0.100 |
Why?
| | Ethics, Research | 1 | 2012 | 34 | 0.100 |
Why?
| | Sensitivity and Specificity | 3 | 2025 | 1977 | 0.100 |
Why?
| | Nasopharynx | 2 | 2023 | 74 | 0.100 |
Why?
| | Age Factors | 2 | 2022 | 3294 | 0.100 |
Why?
| | Linear Models | 1 | 2015 | 858 | 0.090 |
Why?
| | Penicillin Resistance | 1 | 2012 | 8 | 0.090 |
Why?
| | Cystic Fibrosis | 1 | 2022 | 1130 | 0.090 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 178 | 0.090 |
Why?
| | Academic Medical Centers | 1 | 2015 | 531 | 0.090 |
Why?
| | Medical Informatics | 1 | 2012 | 101 | 0.090 |
Why?
| | Drug Therapy | 1 | 2012 | 86 | 0.090 |
Why?
| | Vulnerable Populations | 1 | 2012 | 170 | 0.090 |
Why?
| | Comparative Effectiveness Research | 1 | 2012 | 164 | 0.090 |
Why?
| | Plasma | 1 | 2012 | 221 | 0.090 |
Why?
| | Metagenomics | 2 | 2023 | 182 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 2 | 2024 | 2765 | 0.080 |
Why?
| | Information Systems | 1 | 2009 | 61 | 0.080 |
Why?
| | Acyclovir | 1 | 2009 | 95 | 0.080 |
Why?
| | Health Care Costs | 1 | 2012 | 427 | 0.070 |
Why?
| | Patient Safety | 1 | 2012 | 337 | 0.070 |
Why?
| | Risk Assessment | 3 | 2025 | 3508 | 0.070 |
Why?
| | Overweight | 1 | 2012 | 588 | 0.070 |
Why?
| | Clinical Trials as Topic | 1 | 2012 | 1057 | 0.070 |
Why?
| | Respiration, Artificial | 2 | 2023 | 685 | 0.070 |
Why?
| | Diagnosis, Differential | 2 | 2025 | 1502 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 855 | 0.070 |
Why?
| | Databases, Factual | 1 | 2012 | 1448 | 0.060 |
Why?
| | Time Factors | 3 | 2024 | 6966 | 0.060 |
Why?
| | Lung | 3 | 2024 | 4137 | 0.060 |
Why?
| | Chemokine CXCL10 | 1 | 2025 | 38 | 0.060 |
Why?
| | Hospital Mortality | 2 | 2020 | 924 | 0.060 |
Why?
| | Video Recording | 1 | 2026 | 198 | 0.060 |
Why?
| | Clinical Competence | 1 | 2012 | 1205 | 0.050 |
Why?
| | Respiratory Rate | 1 | 2024 | 21 | 0.050 |
Why?
| | Arkansas | 1 | 2024 | 20 | 0.050 |
Why?
| | Adult | 6 | 2026 | 39391 | 0.050 |
Why?
| | Drug Resistance, Microbial | 1 | 2024 | 65 | 0.050 |
Why?
| | Antiviral Agents | 1 | 2009 | 747 | 0.050 |
Why?
| | Young Adult | 4 | 2025 | 13749 | 0.050 |
Why?
| | Uncertainty | 1 | 2024 | 139 | 0.050 |
Why?
| | Canada | 1 | 2024 | 429 | 0.050 |
Why?
| | Cotinine | 1 | 2023 | 78 | 0.050 |
Why?
| | Patient Acuity | 1 | 2022 | 47 | 0.050 |
Why?
| | Tachypnea | 1 | 2022 | 3 | 0.050 |
Why?
| | Viral Load | 1 | 2024 | 506 | 0.050 |
Why?
| | Smoke | 1 | 2023 | 149 | 0.040 |
Why?
| | Haemophilus influenzae | 1 | 2022 | 63 | 0.040 |
Why?
| | Gestalt Theory | 1 | 2021 | 2 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2026 | 1027 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2023 | 987 | 0.040 |
Why?
| | Disease Outbreaks | 1 | 2024 | 419 | 0.040 |
Why?
| | Adaptive Immunity | 1 | 2022 | 173 | 0.040 |
Why?
| | Feedback | 1 | 2021 | 179 | 0.040 |
Why?
| | Models, Theoretical | 1 | 2024 | 584 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 450 | 0.040 |
Why?
| | Emergency Treatment | 1 | 2021 | 125 | 0.040 |
Why?
| | Medicaid | 1 | 2024 | 451 | 0.040 |
Why?
| | Calcitonin | 1 | 2020 | 29 | 0.040 |
Why?
| | Documentation | 1 | 2022 | 199 | 0.040 |
Why?
| | Heart Rate | 1 | 2024 | 821 | 0.040 |
Why?
| | Fatigue | 1 | 2022 | 339 | 0.040 |
Why?
| | Pneumocystis Infections | 1 | 2019 | 1 | 0.040 |
Why?
| | Antibodies, Bacterial | 1 | 2020 | 146 | 0.040 |
Why?
| | Pseudomonas aeruginosa | 1 | 2022 | 358 | 0.040 |
Why?
| | Diagnostic Tests, Routine | 1 | 2020 | 110 | 0.040 |
Why?
| | Central Venous Catheters | 1 | 2020 | 51 | 0.040 |
Why?
| | Obesity | 1 | 2012 | 3008 | 0.040 |
Why?
| | Acute Disease | 1 | 2022 | 1010 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2020 | 287 | 0.040 |
Why?
| | Regression Analysis | 1 | 2022 | 1023 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 771 | 0.040 |
Why?
| | Pneumonia, Viral | 1 | 2024 | 374 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2019 | 328 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2021 | 558 | 0.040 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2018 | 38 | 0.040 |
Why?
| | Data Display | 1 | 2018 | 20 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2020 | 424 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2018 | 215 | 0.030 |
Why?
| | Gene Expression | 1 | 2022 | 1492 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2026 | 1406 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2020 | 1056 | 0.030 |
Why?
| | Bias | 1 | 2017 | 229 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 2019 | 325 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 799 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2017 | 418 | 0.030 |
Why?
| | Colorado | 1 | 2026 | 4629 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2018 | 308 | 0.030 |
Why?
| | Data Collection | 1 | 2018 | 662 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2019 | 859 | 0.030 |
Why?
| | Antibodies, Viral | 1 | 2018 | 656 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2018 | 900 | 0.030 |
Why?
| | Incidence | 1 | 2020 | 2806 | 0.020 |
Why?
| | Prevalence | 1 | 2020 | 2799 | 0.020 |
Why?
| | Aged | 2 | 2022 | 24746 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2019 | 2007 | 0.020 |
Why?
| | Primary Health Care | 1 | 2020 | 1809 | 0.020 |
Why?
| | Pregnancy | 1 | 2018 | 7092 | 0.010 |
Why?
| | Registries | 1 | 2012 | 2144 | 0.010 |
Why?
|
|
Ambroggio's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|